95 related articles for article (PubMed ID: 11248422)
1. Overexpression of protein kinase A - RIalpha reduces lipofection efficiency of cisplatin-resistant human tumor cells.
Son KK; Rosenblatt J
Cancer Lett; 2001 Apr; 165(1):81-6. PubMed ID: 11248422
[TBL] [Abstract][Full Text] [Related]
2. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.
McDaid HM; Cairns MT; Atkinson RJ; McAleer S; Harkin DP; Gilmore P; Johnston PG
Br J Cancer; 1999 Feb; 79(5-6):933-9. PubMed ID: 10070893
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.
Sasaki H; Niimi S; Akiyama M; Tanaka T; Hazato A; Kurozumi S; Fukushima S; Fukushima M
Cancer Res; 1999 Aug; 59(16):3919-22. PubMed ID: 10463583
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance in cyclic AMP-dependent protein kinase mutants.
Cvijic ME; Yang WL; Chin KV
Pharmacol Ther; 1998 May; 78(2):115-28. PubMed ID: 9623882
[TBL] [Abstract][Full Text] [Related]
6. Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells.
Abe T; Gotoh S; Higashi K
Biochem Pharmacol; 1999 Jul; 58(1):69-76. PubMed ID: 10403520
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
8. Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell.
Yu W; Jin C; Lou X; Han X; Li L; He Y; Zhang H; Ma K; Zhu J; Cheng L; Lin B
PLoS One; 2011; 6(12):e29450. PubMed ID: 22216282
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
10. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
11. Ala99ser mutation in RI alpha regulatory subunit of protein kinase A causes reduced kinase activation by cAMP and arrest of hormone-dependent breast cancer cell growth.
Lee GR; Kim SN; Noguchi K; Park SD; Hong SH; Cho-Chung YS
Mol Cell Biochem; 1999 May; 195(1-2):77-86. PubMed ID: 10395071
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin.
Cvijic ME; Chin KV
Int J Cancer; 1997 Jul; 72(2):345-50. PubMed ID: 9219844
[TBL] [Abstract][Full Text] [Related]
14. Efficient lipofection with cisplatin-resistant human tumor cells.
Huang L; Son K; Gao X; Hages D; Yang YY; Holden SA; Teicher B; Kirkwood J; Lazo JS
Cancer Gene Ther; 1996; 3(2):107-12. PubMed ID: 8729909
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
Nesterova M; Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
[TBL] [Abstract][Full Text] [Related]
17. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
18. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin.
Nikounezhad N; Nakhjavani M; Shirazi FH
J Exp Ther Oncol; 2017 May; 12(1):1-7. PubMed ID: 28472558
[TBL] [Abstract][Full Text] [Related]
19. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
20. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
Nesterova MV; Cho-Chung YS
Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]